Rain Oncology Past Earnings Performance
Past criteria checks 0/6
Rain Oncology's earnings have been declining at an average annual rate of -41.1%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually.
Key information
-41.1%
Earnings growth rate
30.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -107.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?
Feb 23
We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully
Nov 08Rain Therapeutics GAAP EPS of -$0.66 in-line
Aug 04Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation
Aug 03We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
Apr 17We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth
Dec 25We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely
Sep 21Revenue & Expenses BreakdownBeta
How Rain Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -72 | 19 | 55 |
| 30 Jun 23 | 0 | -83 | 19 | 65 |
| 31 Mar 23 | 0 | -79 | 17 | 65 |
| 31 Dec 22 | 0 | -76 | 16 | 61 |
| 30 Sep 22 | 0 | -71 | 15 | 57 |
| 30 Jun 22 | 0 | -71 | 14 | 58 |
| 31 Mar 22 | 0 | -62 | 13 | 49 |
| 31 Dec 21 | 0 | -51 | 11 | 41 |
| 30 Sep 21 | 0 | -39 | 9 | 30 |
| 30 Jun 21 | 0 | -31 | 6 | 23 |
| 31 Mar 21 | 0 | -25 | 4 | 19 |
| 31 Dec 20 | 0 | -21 | 4 | 15 |
Quality Earnings: RAIN is currently unprofitable.
Growing Profit Margin: RAIN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RAIN is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.
Accelerating Growth: Unable to compare RAIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15.2%).
Return on Equity
High ROE: RAIN has a negative Return on Equity (-107.02%), as it is currently unprofitable.